Register for final places for excellent EACPT summer cardiovascular focus meeting 3-5 July in Holland

You are still in time to register for 2014 EACPT Focus Meeting on 'Drugs to Fight Cardiovascular Damage' from organised by the the European Association for Clinical Pharmacology and Therapeutics [EACPT] .

Registration  - with a preferential accommodation rate - is available through the Focus Meeting website.

The 2014 EACPT Focus Meeting takes place from July 3rd - 5th at the Radboud University Medical Center in Nijmegen in the Netherlands.

Reasons to come to this outstanding meeting

• excellent tradition of EACPT in providing outstanding meetings for young and senior clinicians and researchers
• great opportunities for networking with your peers and senior members of the international clinical pharmacology community
• easy access to senior researchers on the international speaker faculty 
• opportunity to have first hand news on major developments for EACPT
• meet Dr Richard Shader, the editor of the EACPT's Official Journal - Clinical Therapeutics 
• expert session from Dr Shader on how to publish

In addition to state-of-the-art lectures from international cardiovascular experts, over 60 delegate abstracts are due be presented  from around the world. The top 5 ranked abstracts will be provided with free registration. All abstracts presented at the meeting will be published in Clinical Therapeutics, the peer-reviewed Official Journal of the EACPT. 

This focus meeting follows on from the highly rated  EACPT international summer school in 2013 in Edinburgh.

The 2014 EACPT Focus Meeting will provide you with the opportunity to attend state of the art lectures from leading professionals and researchers, including hands-on workshops. 

Radboud University Medical Centre, Nijmegen 

Topics include ultrasound imaging of vascular injury (including a hands-on workshop), the microbiome and inflammation in the metabolic syndrome, targeting inflammation to prevent and treat atherosclerosis, diagnosis and therapy of adrenal hypertension, and protection against ischaemia-reperfusion injury.

This EACPT Cardiovascular Focus Meeting is of interest to clinical pharmacologists, pharmacologists, and other young scientists and clinicians interested in drug treatment of cardiovascular disease. 

You can listen here to podcasts with international delegates at the last EACPT summer meeting in Edinburgh in 2013.

See the Scientific Programme is now online on the Focus Meeting website. 

Visit the Clinical Therapeutics website.

Drug Discovery of the Year 2015 opens for nominations

21 May 2014, London UK: The British Pharmacological Society is now accepting nominations from anyone in the world for its third Drug Discovery of the Year award.

The award was established by the Society in 2012 to demonstrate the importance of pharmacology in the development of new medicines, and to reward the achievements of the teams of scientists who discover and develop these drugs.

Previous winners

Drug Discovery of the Year 2013: the Genentech team who developed vismodegib

Drug Discovery of the Year 2014: the GlaxoSmithKline team responsible for trametinib

Professor Humphrey Rang, BPS President, comments: “The British Pharmacological Society was encouraged by the exceptional quality of the nominations received last year. I am delighted to announce the call for submissions to our third Drug Discovery of the Year award and to welcome nominations from across all disease areas that demonstrate the importance of both pre-clinical and clinical pharmacology in translating early discoveries into medicines that benefit patients.”

The Society’s Industry Committee will consider nominations for the discovery team behind a drug – whether a large or a small molecule – that best fulfils the following criteria:

·         preclinical to clinical translation shows the importance of both preclinical and clinical pharmacology in the drug discovery/development process

·         gained regulatory approval within the last three years in the EU and/or US

·         has a significant impact on an unmet medical need

·         first-in-class, or is a significant improvement over other drugs in the class

·         mechanism of action known

Nominations must be received by 1 October 2014. The winning team will be publicly announced during the Society’s flagship meeting Pharmacology 2014, held in London on 16-18 December 2014, and attended by an anticipated 1,000 pharmacologists.

The award does not promote the administration, consumption, prescription, purchase, recommendation, sale, supply or use of the winning medicine; nor does it pre-empt any regulatory decisions. Further information is available from www.bps.ac.uk